Perspectives on Targeted Therapies for Treatment of Human Cancers: Predictors of Response to Targeted Therapies for Gastrointestinal Stromal Tumors.

Posted by rob on January 19, 2012 under Uncategorized | Comments are off for this article

Conclusions.-In gastrointestinal stromal tumors, the strongest predictor of response to targeted therapies is the mutational status of KIT or PDGFRA. Patients whose tumors harbor a KIT exon 11 mutation benefit the most from imatinib mesylate therapy, in terms of response rate, progression-free survival, and overall survival. Conversely, tumors without detectable mutations in either gene (“wild-type” gastrointestinal stromal tumors) are generally not responsive to imatinib mesylate.
PMID: 22229850 [PubMed - as supplied by publisher] (Source: Archives of Pathology and Laboratory Medicine)
More